Rapid Eye Movement Sleep Engages Melanin-Concentrating Hormone Neurons to Reduce Cocaine Seeking.
Accumbens
CP-AMPAR
Closed-loop stimulation
Incubation of cocaine craving
Long-bout REM sleep
MCH
Journal
Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
23
11
2021
revised:
03
06
2022
accepted:
06
06
2022
pubmed:
12
8
2022
medline:
8
11
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Persistent sleep disruptions following withdrawal from abused drugs may hold keys to battle drug relapse. It is posited that there may be sleep signatures that predict relapse propensity, identifying which may open new avenues for treating substance use disorders. We trained male rats (approximately postnatal day 56) to self-administer cocaine. After long-term drug withdrawal (approximately postnatal day 100), we examined the correlations between the intensity of cocaine seeking and key sleep features. To test for causal relationships, we then used behavioral, chemogenetic, or optogenetic methods to selectively increase rapid eye movement sleep (REMS) and measured behavioral and electrophysiological outcomes to probe for cellular and circuit mechanisms underlying REMS-mediated regulation of cocaine seeking. A selective set of REMS features was preferentially associated with the intensity of cue-induced cocaine seeking after drug withdrawal. Moreover, selectively increasing REMS time and continuity by environmental warming attenuated a withdrawal time-dependent intensification of cocaine seeking, or incubation of cocaine craving, suggesting that REMS may benefit withdrawal. Warming increased the activity of lateral hypothalamic melanin-concentrating hormone (MCH) neurons selectively during prolonged REMS episodes and counteracted cocaine-induced synaptic accumulation of calcium-permeable AMPA receptors in the nucleus accumbens-a critical substrate for incubation. Finally, the warming effects were partly mimicked by chemogenetic or optogenetic stimulations of MCH neurons during sleep, or intra-accumbens infusions of MCH peptide during the rat's inactive phase. REMS may encode individual vulnerability to relapse, and MCH neuron activities can be selectively targeted during REMS to reduce drug relapse.
Sections du résumé
BACKGROUND
Persistent sleep disruptions following withdrawal from abused drugs may hold keys to battle drug relapse. It is posited that there may be sleep signatures that predict relapse propensity, identifying which may open new avenues for treating substance use disorders.
METHODS
We trained male rats (approximately postnatal day 56) to self-administer cocaine. After long-term drug withdrawal (approximately postnatal day 100), we examined the correlations between the intensity of cocaine seeking and key sleep features. To test for causal relationships, we then used behavioral, chemogenetic, or optogenetic methods to selectively increase rapid eye movement sleep (REMS) and measured behavioral and electrophysiological outcomes to probe for cellular and circuit mechanisms underlying REMS-mediated regulation of cocaine seeking.
RESULTS
A selective set of REMS features was preferentially associated with the intensity of cue-induced cocaine seeking after drug withdrawal. Moreover, selectively increasing REMS time and continuity by environmental warming attenuated a withdrawal time-dependent intensification of cocaine seeking, or incubation of cocaine craving, suggesting that REMS may benefit withdrawal. Warming increased the activity of lateral hypothalamic melanin-concentrating hormone (MCH) neurons selectively during prolonged REMS episodes and counteracted cocaine-induced synaptic accumulation of calcium-permeable AMPA receptors in the nucleus accumbens-a critical substrate for incubation. Finally, the warming effects were partly mimicked by chemogenetic or optogenetic stimulations of MCH neurons during sleep, or intra-accumbens infusions of MCH peptide during the rat's inactive phase.
CONCLUSIONS
REMS may encode individual vulnerability to relapse, and MCH neuron activities can be selectively targeted during REMS to reduce drug relapse.
Identifiants
pubmed: 35953320
pii: S0006-3223(22)01321-X
doi: 10.1016/j.biopsych.2022.06.006
pmc: PMC9872495
mid: NIHMS1858436
pii:
doi:
Substances chimiques
melanin-concentrating hormone
67382-96-1
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-894Subventions
Organisme : NIDA NIH HHS
ID : P50 DA046346
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA023206
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA040620
Pays : United States
Organisme : NIDA NIH HHS
ID : R37 DA023206
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA043826
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA028145
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA047861
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA046491
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA051010
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Références
Drug Alcohol Depend. 2016 Mar 1;160:49-56
pubmed: 26777774
Genomics. 2002 Jun;79(6):785-92
pubmed: 12036292
J Addict Med. 2014 Nov-Dec;8(6):389-94
pubmed: 25369938
Nature. 1999 Jul 15;400(6741):265-9
pubmed: 10421368
Pharmacol Biochem Behav. 2013 Aug;109:8-15
pubmed: 23603033
Biol Psychiatry. 2019 Jun 1;85(11):915-924
pubmed: 30846301
Nat Rev Neurosci. 2016 Jun;17(6):351-65
pubmed: 27150400
Neuroscience. 2019 May 15;406:314-324
pubmed: 30890480
eNeuro. 2016 Oct 25;3(5):
pubmed: 27822496
Sleep. 1995 Dec;18(10):890-4
pubmed: 8746397
Eur J Neurosci. 2000 Apr;12(4):1194-216
pubmed: 10762350
Curr Biol. 2018 Jul 23;28(14):2263-2273.e4
pubmed: 30017485
Minn Med. 2017 May;100(3):38-39
pubmed: 30452139
Front Syst Neurosci. 2015 Jan 08;8:244
pubmed: 25620917
J Neurosci. 2012 Jan 18;32(3):1035-42
pubmed: 22262901
Sleep Med Rev. 2003 Dec;7(6):523-39
pubmed: 15018094
Mol Pharmacol. 2020 Oct;98(4):445-453
pubmed: 32198209
Int J Endocrinol. 2013;2013:983964
pubmed: 23935621
Nat Commun. 2020 Sep 7;11(1):4448
pubmed: 32895370
Front Psychol. 2019 Aug 02;10:1766
pubmed: 31428021
Nat Commun. 2018 Oct 8;9(1):4129
pubmed: 30297727
Front Neurosci. 2019 Apr 24;13:336
pubmed: 31105512
Brain Res. 2005 Jul 19;1050(1-2):64-71
pubmed: 15975563
Neuroscience. 2015 Mar 19;289:392-405
pubmed: 25613687
Am J Drug Alcohol Abuse. 2008;34(6):692-702
pubmed: 18850496
J Addict Dis. 1992;11(4):21-45
pubmed: 1486092
Biol Psychiatry. 2021 Jun 15;89(12):1138-1149
pubmed: 33715826
Trends Neurosci. 2011 Aug;34(8):411-20
pubmed: 21764143
Mol Psychiatry. 2021 Jul;26(7):3152-3168
pubmed: 33093653
J Neurosci. 2010 Jun 16;30(24):8263-73
pubmed: 20554878
Sleep Med. 2007 Jun;8(4):291-301
pubmed: 17468047
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13305-10
pubmed: 21788501
Exp Clin Psychopharmacol. 2004 Aug;12(3):180-9
pubmed: 15301635
Nat Med. 2002 Aug;8(8):825-30
pubmed: 12118247
Nature. 2005 Oct 27;437(7063):1264-71
pubmed: 16251951
Prog Brain Res. 2012;198:79-121
pubmed: 22813971
J Neurosci. 2011 Apr 13;31(15):5737-43
pubmed: 21490215
Science. 2019 Sep 20;365(6459):1308-1313
pubmed: 31604241
Addict Biol. 2015 Jul;20(4):747-55
pubmed: 24797355
Pharmacopsychiatry. 2012 Jul;45(5):167-76
pubmed: 22290199
Med Hypotheses. 2010 May;74(5):928-33
pubmed: 19910125
J Mol Neurosci. 2011 Jan;43(1):115-21
pubmed: 20582487
J Affect Disord. 2019 Feb 15;245:757-763
pubmed: 30448760
J Neurosci. 2013 Jun 19;33(25):10257-63
pubmed: 23785141
Brain Res. 2011 Jan 19;1369:112-8
pubmed: 21078307
Biol Psychiatry. 2019 Jun 1;85(11):925-935
pubmed: 30219208
Nat Commun. 2019 Oct 29;10(1):4923
pubmed: 31664021
J Neurosci. 2015 Sep 30;35(39):13300-10
pubmed: 26424879
Neuropsychopharmacology. 2019 Jun;44(7):1189-1197
pubmed: 30728447
Cell Metab. 2018 Jul 03;28(1):55-68.e7
pubmed: 29861386
Sleep Med Rev. 2011 Jun;15(3):139-42
pubmed: 21482156
J Clin Psychol. 1971 Oct;27(4):455-6
pubmed: 5115648
Addict Sci Clin Pract. 2016 Apr 26;11(1):9
pubmed: 27117064
Nature. 2001 Jul 12;412(6843):141-2
pubmed: 11449260
Nat Commun. 2018 Apr 20;9(1):1576
pubmed: 29679009
Nature. 2013 Jul 18;499(7458):295-300
pubmed: 23868258
Nat Neurosci. 2013 Nov;16(11):1637-43
pubmed: 24056699
Front Neurosci. 2015 Dec 17;9:475
pubmed: 26733789
Sleep Med. 2018 Feb;42:31-37
pubmed: 29458743
Neuroscientist. 2014 Jun;20(3):203-19
pubmed: 24598308
Neuropsychopharmacology. 2005 May;30(5):927-35
pubmed: 15647749
J Clin Sleep Med. 2007 Feb 15;3(1):24-32
pubmed: 17557449
Neuropsychopharmacology. 2023 Jan;48(1):61-78
pubmed: 35710601
J Neurosci. 2008 Sep 10;28(37):9101-10
pubmed: 18784290
Am J Drug Alcohol Abuse. 2006;32(1):111-20
pubmed: 16450646
Physiol Behav. 1981 Apr;26(4):687-90
pubmed: 7267757
Neuropsychopharmacology. 1998 Jul;19(1):48-59
pubmed: 9608576
Sleep. 2016 Nov 01;39(11):2021-2031
pubmed: 27568801
PLoS One. 2010 Jul 26;5(7):e11766
pubmed: 20668680
Eur J Neurosci. 2005 May;21(10):2807-16
pubmed: 15926928
Prog Neurobiol. 1980;14(2-3):69-97
pubmed: 6999537
Neuropharmacology. 2004;47 Suppl 1:214-26
pubmed: 15464139
Front Mol Neurosci. 2012 Jun 27;5:72
pubmed: 22754497
Neuropsychopharmacology. 2006 Jan;31(1):129-38
pubmed: 15920500
J Sleep Res. 2019 Dec;28(6):e12846
pubmed: 30932254
Physiol Rev. 2021 Jul 1;101(3):995-1046
pubmed: 32790576
Cereb Cortex. 2011 Jan;21(1):115-23
pubmed: 20421251
Neuropsychopharmacology. 2016 Jun;41(7):1779-89
pubmed: 26585289
Curr Biol. 2019 Jun 17;29(12):1976-1987.e4
pubmed: 31155350
Biol Psychiatry. 2018 Jun 15;83(12):987-996
pubmed: 29373120
Cell. 2016 Sep 22;167(1):47-59.e15
pubmed: 27616062
Am J Psychiatry. 2010 Mar;167(3):331-40
pubmed: 20080983
Neurosci Biobehav Rev. 2004 Jan;27(8):765-76
pubmed: 15019426
PLoS One. 2012;7(9):e45471
pubmed: 23029032
Nature. 2008 Jul 3;454(7200):118-21
pubmed: 18500330
Neurochem Int. 2011 Oct;59(5):686-94
pubmed: 21740944
Mol Psychiatry. 2021 Nov;26(11):6198-6208
pubmed: 34385601
Yale J Biol Med. 2015 Nov 24;88(4):415-22
pubmed: 26604867
Sleep Med Rev. 2014 Jun;18(3):195-213
pubmed: 23809904
Neuroendocrinology. 2020;110(3-4):258-270
pubmed: 31154452
Transl Res. 2021 Aug;234:58-73
pubmed: 33711513
Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2418-22
pubmed: 19188611
Sleep Med Rev. 2020 Aug;52:101305
pubmed: 32259697
Curr Opin Neurobiol. 1996 Apr;6(2):228-36
pubmed: 8725965
Curr Biol. 2013 Sep 9;23(17):R774-88
pubmed: 24028961
Front Psychol. 2020 Jul 21;11:1662
pubmed: 32793050
Sleep. 2013 Dec 01;36(12):1767-8
pubmed: 24293745
Nat Commun. 2017 Sep 29;8(1):734
pubmed: 28963505
J Neurosci. 2014 May 14;34(20):6896-909
pubmed: 24828644
J Neurosci. 2005 Mar 16;25(11):2933-40
pubmed: 15772353
Front Syst Neurosci. 2017 Jul 06;11:50
pubmed: 28729827
Proc Natl Acad Sci U S A. 2016 May 3;113(18):5089-94
pubmed: 27091967
Elife. 2013 Dec 31;2:e01462
pubmed: 24381247
eNeuro. 2021 Aug 11;8(4):
pubmed: 34290059
Psychopharmacology (Berl). 2008 May;198(1):63-75
pubmed: 18265959
Neuropharmacology. 2011 Dec;61(7):1141-51
pubmed: 21276808
Neuropharmacology. 2014 Jan;76 Pt B:287-300
pubmed: 23727437
JAMA. 2000 Oct 4;284(13):1689-95
pubmed: 11015800
J Neurosci. 2017 Nov 8;37(45):10867-10876
pubmed: 29118216
Neuropsychopharmacology. 2013 Aug;38(9):1698-705
pubmed: 23481437
Mol Psychiatry. 2022 Jan;27(1):669-686
pubmed: 33963288
J Comp Neurol. 1992 May 8;319(2):218-45
pubmed: 1522246
J Comp Neurol. 2001 Jun 18;435(1):26-40
pubmed: 11370009
Neuron. 2014 Sep 17;83(6):1453-67
pubmed: 25199705
J Psychopharmacol. 1998;12(1):15-22
pubmed: 9584964
Pharmacol Rev. 2022 Jan;74(1):119-140
pubmed: 34987089
Pharmacol Biochem Behav. 2009 Dec;94(2):262-70
pubmed: 19751755
Drug Alcohol Depend. 2011 May 1;115(1-2):62-6
pubmed: 21144676